Profile data is unavailable for this security.
About the company
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
- Revenue in USD (TTM)0.00
- Net income in USD-30.55m
- Incorporated2015
- Employees14.00
- LocationIterum Therapeutics PLCFitzwilliam Court1st Floor, Leeson Close, Dublin 2DUBLIN D02 YW24IrelandIRL
- Phone+353 16694820
- Websitehttps://www.iterumtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intensity Therapeutics Inc | 0.00 | -16.26m | 37.18m | 5.00 | -- | 13.47 | -- | -- | -1.18 | -1.18 | 0.00 | 0.2005 | 0.00 | -- | -- | 0.00 | -147.61 | -- | -171.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -7.42m | 37.23m | 4.00 | -- | -- | -- | -- | -0.3566 | -0.3566 | 0.00 | -0.0334 | 0.00 | -- | -- | 0.00 | -559.23 | -- | -- | -- | -- | -- | -- | -- | -- | -2.13 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Lumos Pharma Inc | 2.21m | -34.92m | 37.45m | 30.00 | -- | 7.62 | -- | 16.98 | -4.29 | -4.29 | 0.2705 | 0.5682 | 0.0676 | -- | 12.75 | 66,818.18 | -107.08 | -29.78 | -132.78 | -32.32 | -- | -- | -1,583.49 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -27.95m | 37.66m | 41.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -1.10 | 0.00 | -- | -- | 0.00 | -208.29 | -- | -2,279.15 | -- | -- | -- | -- | -- | -- | -28.13 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| FibroGen Inc | 180.01m | -121.79m | 38.88m | 486.00 | -- | -- | -- | 0.216 | -1.23 | -1.23 | 1.81 | -2.42 | 0.4967 | 1.29 | 7.49 | 370,399.20 | -34.51 | -30.62 | -103.81 | -42.31 | 76.87 | 93.52 | -69.48 | -119.08 | 1.16 | -7.70 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.92m | 38.90m | 2.00 | -- | 20.49 | -- | -- | -0.306 | -0.306 | 0.00 | 0.0732 | 0.00 | -- | -- | 0.00 | -137.58 | -- | -154.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 38.91m | 37.00 | -- | 0.9077 | -- | 5.26 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -30.55m | 40.19m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.5068 | 0.00 | -- | -- | 0.00 | -109.80 | -118.12 | -297.32 | -199.23 | -- | -- | -- | -890,554.10 | -- | -7.38 | 2.05 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Xilio Therapeutics Inc | 4.62m | -62.80m | 40.44m | 73.00 | -- | 1.93 | -- | 8.75 | -1.72 | -1.72 | 0.1046 | 0.4771 | 0.0606 | -- | -- | 63,287.67 | -82.36 | -- | -128.76 | -- | -- | -- | -1,359.37 | -- | -- | -320.73 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Rallybio Corp | 598.00k | -66.97m | 41.01m | 25.00 | -- | 0.5792 | -- | 68.59 | -1.59 | -1.59 | 0.0141 | 1.71 | 0.0056 | -- | -- | 13,906.98 | -63.12 | -- | -68.83 | -- | -- | -- | -11,199.50 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -33.38m | 41.47m | 15.00 | -- | -- | -- | -- | -1.12 | -1.12 | 0.00 | -0.2985 | 0.00 | -- | -- | 0.00 | -512.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.37m | 42.06m | 29.00 | -- | 4.72 | -- | -- | -1.13 | -1.13 | 0.00 | 0.3432 | 0.00 | -- | -- | 0.00 | -150.14 | -- | -236.03 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0526 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Vyne Therapeutics Inc | 493.00k | -33.95m | 42.78m | 10.00 | -- | 0.6733 | -- | 86.77 | -0.8493 | -0.8509 | 0.0124 | 4.31 | 0.0103 | -- | -- | 49,300.00 | -71.12 | -108.41 | -88.91 | -138.57 | -- | -- | -6,885.40 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Omega Therapeutics Inc | 8.10m | -73.09m | 42.80m | 93.00 | -- | 3.71 | -- | 5.29 | -1.33 | -1.33 | 0.1468 | 0.2093 | 0.0437 | -- | 18.34 | 87,043.01 | -39.45 | -- | -45.75 | -- | -- | -- | -902.93 | -- | -- | -- | 0.5745 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Iterum Therapeutics PLC's reporting currency: US Dollar USD
7.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 1.34m | 5.90% |
| Apollon Financial LLCas of 30 Sep 2024 | 224.75k | 0.99% |
| Alpine Global Management LLCas of 30 Sep 2024 | 64.83k | 0.29% |
| XTX Markets LLCas of 30 Sep 2024 | 33.04k | 0.15% |
| Two Sigma Securities LLCas of 30 Sep 2024 | 14.95k | 0.07% |
| Geode Capital Management LLCas of 30 Sep 2024 | 12.37k | 0.05% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 5.48k | 0.02% |
| Activest Wealth Management LLCas of 30 Sep 2024 | 133.00 | 0.00% |
| Wells Fargo Clearing Services LLCas of 30 Sep 2024 | 85.00 | 0.00% |
| Cypress Capital Management LLC (Wyoming)as of 30 Sep 2024 | 66.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
